Nivolumab (nivo) +/- ipilimumab (ipi) in pre-treated patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs) (GCO-001 NIPINEC)

Affiliation auteurs!!!! Error affiliation !!!!
TitreNivolumab (nivo) +/- ipilimumab (ipi) in pre-treated patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs) (GCO-001 NIPINEC)
Type de publicationJournal Article
Year of Publication2021
AuteursGirard N., Mazieres J., Otto J., Lena H., Lepage C., Egenod T., Smith D., Madelaine J., Geriniere L., F. Hajbi E, Ferru A., Clement-Duchene C., Madroszyk A., Desrame J., Morin F., Langlais A., Michel P., Louvet C., Westeel V., Walter T.
JournalANNALS OF ONCOLOGY
Volume32
PaginationS1318
Type of ArticleMeeting Abstract
ISSN0923-7534
DOI10.1016/j.annonc.2021.08.2119